The latest in a string of clinical failures in the pancreatic cancer space, Aduro Biotech Inc.'s phase IIb miss was made more frustrating by a high dropout rate in the control arm that renders any readthrough to other trials testing LADD-based therapeutic CRS-207 nearly impossible.